U.S. Markets open in 3 hrs 17 mins

Harte Hanks, Inc. (HHS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
2.69000.0000 (0.00%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.6900
Open2.6500
Bid0.0000 x 1800
Ask0.0000 x 3000
Day's Range2.6000 - 2.7900
52 Week Range1.1000 - 4,550.0000
Volume12,585
Avg. Volume43,376
Market Cap17.328M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Harte Hanks To Announce Second Quarter 2020 Results and Host Investor Conference Call on August 13, 2020
    PR Newswire

    Harte Hanks To Announce Second Quarter 2020 Results and Host Investor Conference Call on August 13, 2020

    Harte Hanks (OTCQX: HRTH), a leading data-driven multi-channel marketing solutions firm, announced today that the company will release financial results for the second quarter ended June 30, 2020 on Thursday, August 13, 2020 after the close of the market.

  • Harte Hanks, Inc. Announces Suspension Of Trading And Commencement Of NYSE Delisting Procedures; Common Stock Expected To Begin Trading On The OTCQX
    PR Newswire

    Harte Hanks, Inc. Announces Suspension Of Trading And Commencement Of NYSE Delisting Procedures; Common Stock Expected To Begin Trading On The OTCQX

    Harte Hanks, Inc. (NYSE: HHS) (the "Company" or "Harte Hanks"), a leading data-driven multi-channel marketing solutions firm, today announced the Company was notified by the New York Stock Exchange ("NYSE") on July 9, 2020, that the NYSE had determined to commence proceedings to delist the Company's common stock (the "Common Stock") as a result of the Company's failure to comply with the continued listing standard set forth in Section 802.02B of the NYSE Listed Company Manual to maintain either (i) at least $50 million in stockholders' equity or (ii) at least $50 million in total market capitalization on a 30-trading day average basis. The NYSE will announce a suspension date at such time as (i) the Company does not request a review of the determination by the Committee of the Board of Directors of the NYSE (the "Committee") within 10 business days of the notice, (ii) the Company determines that it does not intend to appeal the determination, (iii) the subsequent review of the Committee determines that the Company should be suspended or, (iv) there are other material developments.

  • GlobeNewswire

    Flagship Biosciences chooses Harte Hanks as marketing solutions partner.

    Harte Hanks, Inc. (HHS), a leading behavioral marketing company, announced today that it has been selected by Flagship Biosciences to provide strategic marketing solutions in developing a new customer acquisition program. Flagship Biosciences is a leader in technology-driven tissue analysis, and provides expert tissue data insights to pharmaceutical, biotechnology and clinical diagnostic companies. Harte Hanks will be developing a targeted, multi-channel campaign including email, digital advertising and content creation to help Flagship Biosciences engage priority audiences, nurture leads and connect with potential clients.